Log in
Lost password
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Shares  >  TEL AVIV STOCK EXCHANGE  >  Teva Pharmaceutical Industries Limited    TEVA

News SummaryMost relevantAll newsSector news 

Illumina: Teva Pharmaceutical Exclusive Distributor of Verifi Test in Israel

07/01/2013 | 07:27am US/Eastern
   By Melodie Warner 

Illumina Inc. (>> Illumina, Inc.) said Teva Pharmaceutical Industries Ltd. (>> Teva Pharmaceutical Industries Ltd (ADR)) will be the exclusive distributor of the verifi prenatal test in Israel under a five-year agreement.

Financial terms weren't disclosed.

Illumina paid $350 million in February to buy Verinata Health Inc., which gave it access to Verinata's verifi prenatal test, the broadest non-invasive prenatal test currently available for high-risk pregnancies.

The company said the MOR Institute for Medical Data Ltd., through its relationship with Teva, will provide the verifi test to customers of Clalit Health Services who are at high risk of having a fetus with a chromosomal abnormality.

The MOR Institute will also establish a 9,000-patient clinical outcomes registry to collect performance data and will share the data with Verinata.

Illumina said the patient registry developed through this collaboration will be the largest and most extensive of its kind.

Illumina shares closed Friday at $74.84 and were inactive premarket. The stock is up 35% this year.

Write to Melodie Warner at melodie.warner@dowjones.com

Stocks mentioned in the article : Illumina, Inc., Teva Pharmaceutical Industries Ltd (ADR)
React to this article
08/01 ALLERGAN : BRIEF: Teva secures $34b financing for Allergan acquisition
07/31 TEVA PHARMACEUTICAL : Secures $33.75 Billion Financing Commitment
07/31 Healthcare deals lift July to seventh busiest M&A month on record
07/31 TEVA PHARMACEUTICAL : Reports European Medicines Agency Confirms Validation of R..
07/30DJAmgen Raises 2015 Outlook, Results Beat Expectations
07/30DJTeva Profit Falls on Legal Expenses
07/30DJTeva Profit Falls as Legal and Restructuring Expenses Rise
07/30 Teva's MS drug Copaxone has strong second-quarter sales
07/30 TEVA PHARMACEUTICAL : Reports Strong Second Quarter 2015 Results and Raises Guid..
07/29 TEVA PHARMACEUTICAL : to Report Second Quarter 2015 Financial Results on July 30..
Duration : Period :
Teva Pharmaceutical Indust Technical Analysis Chart | TEVA | IL0006290147 | 4-Traders
Income Statement Evolution
More Financials